BRIDGEWATER, N.J. — Sanofi U.S. on Tuesday announced that it has launched an authorized generic version of Eloxatin (oxaliplatin injection) through Winthrop U.S., the company’s generics division. Sanofi’s authorized generic version is the same formulation as the original drug, Eloxatin, for which the company holds the original patent.
Eloxatin is a platinum–based drug used in combination with infusional 5–fluorouracil/leucovorin. This treatment is indicated for treatment of advanced colorectal cancer or as adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. The authorized generic version of Eloxatin will be available in the same sizes, 50-mg and 100-mg single–use vials.
“We are committed to broadening access to our medicines and providing more affordable treatment options for patients,” stated Charles Hugh-Jones, chief medical officer, North America, Sanofi. “The availability of an authorized generic version of Eloxatin is welcomed news for patients and physicians alike.”